Author

T. Huijs

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 2 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 3 Approach:experimental assay· 2 Organism:plant (other)· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Approach:deep learning· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1

Frequent Co-Authors

B. Laleu· 2 shared K. J. Dechering· 2 shared R. Henderson· 2 shared S. Wittlin· 2 shared A. C. Aguiar· 1 shared A. Chakraborty· 1 shared A. Churchyard· 1 shared A. Karabina· 1 shared

Activity by Year

2021-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersPharmacology & Toxicology

B. Laleu

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

A small-molecule myosin inhibitor as a targeted multi-stage antimalarial

D. V. Trivedi, A. Karabina, G. Bergnes, A. Racca, H. Wander, S. Jung, N. Mittal, T. Huijs, S. Ouchida, P. V. Ruijgrok, D. Song, S. Wittlin, P. Mukherjee, A. Chakraborty, E. A. Winzeler, , J. Spudich

This paper develops a small-molecule myosin inhibitor, KNX-115, effective against multiple stages of Plasmodium infection with high selectivity and potency.

bioRxiv · Sep 9, 2022 · PreprintPharmacology & Toxicology

Replenishing the malaria drug discovery pipeline: Screening and hit evaluation of the MMV Hit Generation Library 1 (HGL1) against asexual blood stage Plasmodium falciparum, using a nano luciferase reporter read-out

K. J. Dechering, M. Timmerman, K. Rensen, K. M. J. Koolen, S. Honarnejad, M. Vos, T. Huijs, R. Henderson, E. Chenu, B. Laleu, B. C. Montefiore, M. D. Segall, J. E. J. Mills, E. M. Guantai, J. Duffy, M. Duffey

The paper screens a compound library against Plasmodium falciparum using a nanoluciferase assay, identifying 33 high-quality hits for antimalarial drug development.

bioRxiv · Jun 7, 2022Microbiology

Preclinical characterization and target validation of the antimalarial pantothenamide MMV693183

L. E. de Vries, P. A. Jansen, C. Barcelo, J. Munro, J. M. Verhoef, C. F. A. Pasaje, K. Rubiano, J. Striepen, J. M. Bolscher, R. Henderson, T. Huijs, K. M. Koolen, P. K. Tumwebaze, T. Yeo, A. C. Aguiar, , K. J. Dechering

This paper characterizes MMV693183, a novel antimalarial compound targeting acetyl-CoA synthetase, showing in vitro and in vivo efficacy against Plasmodium species and transmission blocking.

bioRxiv · May 12, 2021Microbiology